The role of BDNF, leptin, and catecholamines in reward learning in bulimia nervosa by Homan, P et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
The role of BDNF, leptin, and catecholamines in reward learning in bulimia
nervosa
Homan, P; Grob, S; Milos, G; Schnyder, U; Eckert, A; Lang, U; Hasler, G
Abstract: Unspecified
DOI: 10.1093/ijnp/pyu092
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-115437
Published Version
 
 
Originally published at:
Homan, P; Grob, S; Milos, G; Schnyder, U; Eckert, A; Lang, U; Hasler, G (2015). The role of BDNF,
leptin, and catecholamines in reward learning in bulimia nervosa. International Journal of Neuropsy-
chopharmacology, 18(5):pyu092. DOI: 10.1093/ijnp/pyu092
Received: August 8, 2014; Revised: October 28, 2014; Accepted: October 30, 2014
© The Author 2015. Published by Oxford University Press on behalf of CINP.
International Journal of Neuropsychopharmacology, 2015, 1–8
doi:10.1093/ijnp/pyu092
Research Article
1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any 
medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
research article
The Role of BDNF, Leptin, and Catecholamines in 
Reward Learning in Bulimia Nervosa
Philipp Homan, MD, PhD; Simona Grob, MSc; Gabriella Milos, MD; 
Ulrich Schnyder, MD; Anne Eckert, PhD; Undine Lang, MD, PhD; 
Gregor Hasler, MD
Department of Molecular Psychiatry, University Hospital of Psychiatry, University of Bern, Switzerland (Drs 
Homan and Hasler); Department of Psychiatry and Psychotherapy, University Hospital, Zurich, Switzerland 
(Dr Grob, Drs Milos and Schnyder); Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric 
University Clinics Basel, Switzerland (Dr Eckert); Psychiatric University Clinics Basel, Switzerland (Dr Lang).
Correspondence: Philipp Homan, MD, PhD, Department of Molecular Psychiatry, University Hospital of Psychiatry, University of Bern, Bolligenstrasse 111, 
3000 Bern, Switzerland (homan@puk.unibe.ch).
Abstract
Background: A relationship between bulimia nervosa and reward-related behavior is supported by several lines of evidence. 
The dopaminergic dysfunctions in the processing of reward-related stimuli have been shown to be modulated by the 
neurotrophin brain derived neurotrophic factor (BDNF) and the hormone leptin.
Methods: Using a randomized, double-blind, placebo-controlled, crossover design, a reward learning task was applied to 
study the behavior of 20 female subjects with remitted bulimia nervosa and 27 female healthy controls under placebo and 
catecholamine depletion with alpha-methyl-para-tyrosine (AMPT). The plasma levels of BDNF and leptin were measured 
twice during the placebo and the AMPT condition, immediately before and 1 hour after a standardized breakfast.
Results: AMPT–induced differences in plasma BDNF levels were positively correlated with the AMPT–induced differences 
in reward learning in the whole sample (P = .05). Across conditions, plasma brain derived neurotrophic factor levels were 
higher in remitted bulimia nervosa subjects compared with controls (diagnosis effect; P = .001). Plasma BDNF and leptin levels 
were higher in the morning before compared with after a standardized breakfast across groups and conditions (time effect; 
P < .0001). The plasma leptin levels were higher under catecholamine depletion compared with placebo in the whole sample 
(treatment effect; P = .0004).
Conclusions: This study reports on preliminary findings that suggest a catecholamine-dependent association of plasma 
BDNF and reward learning in subjects with remitted bulimia nervosa and controls. A role of leptin in reward learning is not 
supported by this study. However, leptin levels were sensitive to a depletion of catecholamine stores in both remitted bulimia 
nervosa and controls.
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Introduction
Bulimia nervosa (BN) is a complex eating disorder and its 
etiology is still largely unknown. A biological basis is widely 
accepted, and therefore an extensive effort has been taken to 
study neurotransmitters, neuropeptides, and neuromodulators 
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implicated in the regulation of eating behavior. Eating behav-
ior is influenced not only by metabolic but also nonmetabolic 
factors (Monteleone and Maj, 2013), including cognition, emo-
tion, and reward. Specifically, food intake can be triggered by 
reward-related processes even in the absence of a homeo-
static requirement. Appetite-regulating substances such as 
brain derived neurotrophic factor (BDNF) and leptin have been 
shown to additionally mediate the rewarding aspects of food 
(Monteleone and Maj, 2013) by promoting the food intake of 
highly rewarding food rich in sugar or fat. In line with this, 
BN can be conceptualized as a disease where binge eating is 
aimed at reducing the patient’s negative emotions by increas-
ing food-derived feelings of pleasure. Negative emotions might 
be associated with a dysfunctional processing of rewards. 
Consequently, several lines of evidence support a relation-
ship between BN and alterations in reward-related behavior 
(Harrison et al., 2010; Wagner et al., 2010; Grob et al., 2012). We 
have previously shown a dopamine-related deficit in reward 
learning in subjects with remitted BN (rBN) (Grob et al., 2012). 
Critically, the dopaminergic dysfunctions in the processing of 
reward-related stimuli have been shown to be modulated by 
BDNF and leptin. BDNF, a neurotrophin involved in neuronal 
outgrowth and differentiation, synaptic connectivity, and neu-
ronal repair, plays a role in dopaminergic neurons within the 
mesolimbic reward pathway, including the ventral tegmental 
area (VTA) and their projections to the nucleus accumbens 
(NAc) and medial prefrontal cortex (Rios, 2013). The mes-
olimbic reward pathway is involved in what has been termed 
hedonic feeding, that is, the intake of highly rewarding food 
even in the absence of a metabolic requirement (Bassareo and 
Di Chiara, 1999; Rada et al., 2005). Within this circuitry, BDNF 
is expressed in the VTA and medial prefrontal cortex and is 
anterogradely transported to the NAc where little or no BDNF 
is expressed (Rios, 2013). Specifically, BDNF levels in dopamin-
ergic cells within the VTA/NAc pathway seem to be related to 
the neuroadaptive changes following reward responses in ani-
mal models (Blochl and Sirrenberg, 1996; Horger et al., 1999; 
Cordeira et al., 2010). In humans, there is initial evidence sug-
gesting that the decreased BDNF activity in carriers of a valine-
methionine polymorphism at codon 66 results in a decreased 
dopamine tone in the NAc (Pecina et al., 2014).
Leptin, on the other hand, an adipocyte-derived hormone 
involved in the regulation of energy balance (Blundell et  al., 
2001), has also been reported to modulate reward-related behav-
ior. Within the mesolimbic pathway, leptin receptors have been 
detected on the VTA dopaminergic neurons (Scott et al., 2009), 
suggesting that leptin decreases the firing of mesolimbic dopa-
minergic neurons as well as the dopamine release and concen-
trations in the NAc (Krugel et al., 2003). This might ultimately 
lead to a negative modulation of reward-related behaviors in 
animals (Carroll et  al., 1984; Fulton et  al., 2000; Cowley et  al., 
2001; Shalev et al., 2001; Figlewicz et al., 2006; Davis et al., 2011) 
and humans (Farooqi et al., 2007).
The current study aimed at elucidating the roles of BDNF, 
leptin, and dopamine in reward-related behavior of rBN sub-
jects. To this end, we used a reward learning task to study the 
participants’ behavior as a function of reward (Pizzagalli et al., 
2005) during a pharmacological challenge with placebo and 
alpha-methyl-para-tyrosine (AMPT) (Berman et  al., 1999) that 
has been shown to deplete central dopamine and norepineph-
rine stores (Stine et al., 1997; Verhoeff et al., 2003). In addition, 
we measured the plasma levels of BDNF and leptin twice dur-
ing the placebo and AMPT conditions, immediately before and 1 
hour after a standardized breakfast.
Since we were not aware of any studies that have measured 
the relationship of BDNF and leptin in reward-related behavior 
of rBN subjects, the corresponding analyses were performed in 
an exploratory fashion. Previous studies did, however, measure 
the plasma and serum levels of BDNF and leptin in subjects 
with BN, but the results were inconsistent for BDNF (Nakazato 
et al., 2003; Monteleone et al., 2005; Mercader et al., 2007; Saito 
et al., 2009; Yamada et al., 2012), whereas plasma leptin levels 
were found to be decreased (Jimerson et al., 2000; Monteleone 
et al., 2000a 2000b). Consequently, and because of the fact that 
our study differed from previous studies by measuring non-
medicated BN subjects that were in remission, the BDNF and 
leptin plasma analyses were also performed in an exploratory 
fashion.
Methods
Participants
We used the data from the study sample described in (Grob 
et al., 2012) that also overlaps with other previously published 
results (Grob et  al., 2013; Homan et  al., 2013). We recruited 
females aged 19 to 39  years who had previously met DSM-IV 
criteria for BN and had been in remission from BN for at least 
6 months (n = 20) or who had no history of any psychiatric disor-
der and no major psychiatric condition in first-degree relatives 
(control subjects; n = 30). Subjects with rBN had no recurrent 
episodes of binge eating and no recurrent inappropriate com-
pensatory behavior to prevent weight gain during the last 
6 months. The screening visit included a diagnostic Structured 
Clinical Interview for DSM-IV with a psychiatrist and a physi-
cal examination. To obtain comparable samples, participants 
for both study groups were recruited by advertisements in local 
newspapers and announcements at the University of Zurich 
and the Swiss Federal Institute of Technology Zurich. Exclusion 
criteria included current Axis I psychiatric disorders, a lifetime 
diagnosis of psychosis, major medical or neurological illness, 
psychoactive medication exposure within 6  months, preg-
nancy, lifetime history of substance dependence, and suicidal 
ideation or a history of suicide attempts. All subjects gave writ-
ten informed consent before participation. The study protocol 
was approved by the ethics committee of the Canton Zurich 
(Kantonale Ethikkommission Zürich).
Experimental Design
This was a randomized, double-blind, placebo-controlled, 
crossover study during which all subjects underwent 2 identi-
cal sessions separated by at least 7 days wherein they received 
either AMPT or placebo. Each session included a 2-day stay 
at the Department of Psychiatry and Psychotherapy of the 
University Hospital of Zurich. One-bed rooms with a separate 
lavatory were available on a separated floor for all participants, 
and they had no contact with other hospitalized subjects. None 
of the rBN subjects had been previously hospitalized at this 
Department of Psychiatry and Psychotherapy. Participants 
received regular standardized meals during the hospital ses-
sions. Each subject was contacted daily by telephone for 3 sub-
sequent days after each trial for follow-up interviews. To avoid 
any risk of adverse reaction, body weight-adjusted oral doses 
of AMPT of 40 mg/kg, to a maximum of 4 g over 22 hours (at 9:00 
am, 12:00 pm, and 7:00 pm on day 1 and 7:00 am on day 2), were 
administered. During sham depletion, subjects received inac-
tive placebo on day 1 at 9:00 am and 12:00 pm and 25 mg oral 
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diphenhydramine on day 1 at 7:00 pm and on day 2 at 7:00 am to 
imitate the mild sedation effect that is often induced by AMPT. 
To prevent formation of crystalluria during AMPT administra-
tion, the subjects were instructed to drink at least 2 L of water 
daily. Possible adverse reactions were assessed regularly (26, 30, 
54, 78, and 102 hours after the first AMPT/placebo administra-
tion) during hospitalization by medical examination, includ-
ing blood pressure measurement, and for 3 subsequent days 
after each trial session as part of the daily telephone follow-up 
interview.
Blood Samples
During each session, blood samples were drawn before and at 
26 hours after the first AMPT dose (because the depletion effect 
is evident from 24 hours after the first AMPT dose) in order to 
measure plasma BDNF and leptin levels. The first sample was 
drawn immediately before and the second one within 1 hour 
after eating a regular standardized breakfast. Blood samples 
were drawn before the reward learning task.
Plasma BDNF levels were measured using a BDNF Emax 
Immunoassay Kit (Promega, Switzerland; specificity: cross-reac-
tivity to related neurotrophins <3%; sensitivity: detects a mini-
mum of about 15 pg/mL). Plasma leptin concentrations were 
measured using a commercial Radioimmunoassay (Millipore, 
Millipore Corporation, Billerica, MA; specificity: 100%; sensitiv-
ity: detects a minimum of 1.0 ng/mL).
Behavioral Assessment
Depressive symptoms were assessed with the Montgomery-
Åsberg Depression Rating Scale and the Hamilton Scale of 
Depression. In addition, participants completed various self-
report ratings, including the German version of the Eating 
Disorder Examination-Questionnaire (Hilbert, 2006). Symptoms 
were assessed immediately before the first AMPT/placebo dose 
(prechallenge) and at 26, 30, 54, 78, and 102 hours after the first 
dose.
Reward Learning Task
Thirty hours after the first AMPT/placebo administration, 
subjects participated in a 25-minute probabilistic reward 
task presented on a PC using E-prime software that has been 
previously described (Grob et  al., 2012). Briefly, participants 
were instructed that the goal of that task was to win as much 
money as possible. The task included 300 trials divided into 3 
blocks of 100 trials. An asymmetric reinforcement ratio was 
used to induce a response bias, that is, subjects received a 
reward 3 times more frequently for correct identification of a 
rich stimulus than for correct identification of a lean stimu-
lus. Each participant was exposed to the same reward ratio. 
Reward learning was defined as the difference in response 
bias between Block 1 and Block 3 (Pizzagalli et al., 2005 2008; 
Bogdan and Pizzagalli, 2006).
Statistical Analysis
Full factorial linear mixed models with restricted maximum 
likelihood estimation were applied to determine the effects 
of treatment, diagnosis, and treatment-by-diagnosis on BDNF 
and leptin. An additional factor time was included as fixed 
effect to account for the 2 measurements in each condition. 
In all models, a various components or compound symmetry 
covariance structure, chosen considering the lowest Akaike’s 
Information Criterion, was appropriate for the repeated meas-
ures. Subject number and treatment sequence were included 
as random effects in all models. To evaluate the relationship 
between alterations induced by catecholamine depletion in 
hormone levels and reward learning, additional Spearman 
rank correlation coefficients were calculated. Therefore, the 
differences in plasma BDNF and leptin levels between the sec-
ond and first measurement were calculated for each subject 
and each condition. The difference obtained from the AMPT 
condition was then subtracted from the difference obtained 
from the placebo condition, reflecting the AMPT-induced 
change in plasma levels. In the same manner, the differences 
between the reward learning scores obtained for each subject 
in the AMPT session vs the placebo session were calculated to 
reflect the magnitude of AMPT-induced effect on reward learn-
ing. We also assessed the effect that feeding might have had 
on the relationship between plasma BDNF and leptin levels 
and reward learning by calculating the difference of plasma 
BDNF and leptin levels between 10 hours and 7 hours in the 
placebo condition in each subject and by correlating these 
differences with the results of the reward learning task in 
the placebo condition with a Spearman rank correlation. To 
account for the possible influence of past episodes of ano-
rexia nervosa, all analyses were repeated excluding patients 
with a history of anorexia nervosa. The significance threshold 
for these contrasts was set at alpha = 0.05 (2-tailed). SAS 9.3 
(SAS Institute, Cary, NC, http://www.sas.com) was used for all 
analyses. Means are reported with their associated standard 
deviations.
Results
Three control subjects had to be excluded from the study 
because of inadequate or missing (eg, insufficient quantity 
or hemolysis) blood samples in all measurements, leaving 20 
rBN subjects and 27 healthy controls for the measurements of 
plasma BDNF and leptin levels. Four rBN subjects and 2 controls 
had to be excluded from the correlational analysis of reward 
learning, BDNF, and leptin because of missing trials in the 
reward learning task, leaving 16 rBN subjects and 25 healthy 
controls for the correlational analysis. The clinical and demo-
graphic characteristics of study participants, including baseline 
parameters, are detailed in Table 1. The rBN subjects had sig-
nificantly more depressive symptoms at baseline vs the healthy 
controls as measured with the Hamilton Scale of Depression (t 
[1, 45] = 2.51, P = .02), and they had histories of significantly lower 
minimal body mass indexes (BMIs) (t [1, 45] = -2.1, P = .04). The 
rBN subjects retained a significantly greater number of bulimic 
symptoms at study entry compared with the healthy controls (t 
[1, 45] = 2.53, P = .01). Plasma leptin levels at the first measure-
ment at 7 hours during the placebo condition were positively 
correlated with BMI in subjects with rBN (r = 0.88, P < .0001), and 
this correlation approached significance in controls (r = 0.34, 
P = .08). This correlation was also significant for the whole study 
sample (r = 0.63, P < .0001). Effects of AMPT on reward learning 
as well as depressive and bulimic symptoms have been pre-
viously reported (Grob et  al., 2012 2013). Briefly, rBN subjects 
showed significantly lower reward learning (diagnosis-effect; F 
[1, 76] = 10.66, P = .002) across conditions. In addition, there was 
a significant treatment-by-diagnosis interaction (F [1, 76] = 4.94, 
P = .03) that was attributable to significantly lower reward learn-
ing in rBN subjects compared with controls under AMPT (t 
[1, 76] = 3.88, P = .001).
4 | International Journal of Neuropsychopharmacology, 2015
BDNF Concentrations in Plasma and Correlation 
with Reward Learning
At the first measurement at 7 hours during the placebo con-
dition, subjects with rBN had higher levels of BDNF compared 
with healthy controls at a trend level (t [1,  45] = 1.82, P = .08). 
Mean plasma levels of BDNF under catecholamine depletion 
and placebo are shown in Figure  1A. The plasma BDNF levels 
were significantly higher in rBN subjects compared with healthy 
controls across conditions (diagnosis effect; F [1,  181] = 10.71, 
P = .0010) (Figure  1B). In addition, plasma BDNF levels were 
significantly higher across groups and conditions at the first 
measurement at 7 hours after fasting compared with the sec-
ond measurement at 10 hours after a standardized breakfast 
(time effect; F [1,  181] = 43.37, P < .0001). There was no effect of 
treatment (P = .99) and no treatment-by-diagnosis interaction 
(P = .35). After repeating the analysis excluding patients with a 
history of anorexia nervosa, the diagnosis effect decreased (F 
[1, 161] = 3.77, P = .05).
The Spearman rank correlation between the AMPT-induced 
differences in plasma BDNF levels and the AMPT-induced dif-
ferences in reward learning approached significance (rho = 0.3, 
P = .05) (Figure  1B). The correlation between meal-induced 
changes in plasma BDNF levels and reward learning under 
placebo was not significant (P > .1). After repeating the analysis 
excluding patients with a history of anorexia nervosa, this cor-
relation was slightly stronger (rho = 0.33, P < .05). Repeating the 
analysis for each of the diagnostic groups separately did not 
reveal any significant results (all P > .05).
Leptin Concentrations in Plasma and Correlation 
with Reward Learning
At the first measurement at 7 hours during the placebo con-
dition, no difference in plasma leptin levels between rBN 
subjects and controls was evident (P = .79). Mean plasma lev-
els before and after catecholamine depletion are shown in 
Figure  1C. Under catecholamine depletion, the plasma leptin 
levels were significantly higher across groups (treatment effect; 
F [1, 181] = 12.78, P = .0004) (Figure 1C). Plasma leptin levels were 
significantly higher across groups and conditions at the first 
measurement at 7 hours after fasting compared with the second 
measurement at 10 hours after a standardized breakfast (time 
effect; F [1, 181] = 47.5, P <.0001) (Figure 1C). No diagnosis effect 
(P = .92) and no treatment-by-diagnosis interaction (P = .63) were 
evident. An additional analysis excluding patients with a history 
of anorexia nervosa did not change the results.
The Spearman rank correlation between the AMPT-induced 
differences in plasma leptin levels and the AMPT-induced dif-
ferences in reward learning was not significant (P = .37). The cor-
relation between meal-induced changes in plasma leptin levels 
and reward learning under placebo was not significant (P > .1). 
An additional analysis excluding patients with a history of ano-
rexia nervosa did not change the results. Repeating the analysis 
for each of the diagnostic groups separately did not reveal any 
significant results (all P > .05).
Discussion
The current study was the first to investigate the relationship of 
BDNF, leptin, and dopamine in reward-related behavior of rBN 
subjects and controls. We used a pharmacological challenge 
paradigm with AMPT to deplete central dopamine and norepi-
nephrine stores. We found that the AMPT-induced differences 
in plasma BDNF levels were positively correlated at a trend level 
with the AMPT-induced differences in reward learning in the 
whole sample. At the first measurement under placebo, plasma 
BDNF levels were higher at a trend level in rBN subjects com-
pared with controls. Across conditions, plasma BDNF levels 
were significantly higher in rBN subjects compared with con-
trols. Plasma BDNF and leptin levels were significantly higher in 
the morning before breakfast compared with after a standard-
ized breakfast across groups and conditions. The plasma leptin 
levels were higher under catecholamine depletion compared 
with placebo in the whole sample.
Table 1. Demographic and Clinical Characteristics of Unmedicated Subjects with Remitted Bulimia Nervosa (rBN) and Healthy Controls
Characteristic rBN (n = 20) Controls (n = 27) P-value
Sex, n f/m 20/0 27/0 n.a.
Age, mean (SD), y 29.1 (4.7) 28.5 (3.8) 0.65
BMI, mean (SD), kg/m2 21.7 (3.1) 22.2 (2.3) 0.47
BMI min, mean (SD), kg/m2 17.2 (2.2) 19.3 (4.2) 0.04*
BMI max, mean (SD), kg/m2 24.0 (3.5) 22.7 (5.4) 0.35
Age at onset, mean (SD), y 15.5 (4.7) n. a. n.a.
Educational level (SD), y 16.5 (3.1) 17.3 (3.0) 0.4
Time in remission, mo
 Mean (SD) 31.9 (28.1) n. a. n.a.
 Range 6 – 84 n. a. n.a.
History of anorexia nervosa 7 n.a. n.a.
First-degree relative(s) with a history of bulimia nervosa, n 2 0 0.2
First-degree relative(s) with a history of anorexia nervosa, n 2 0 0.2
Remote (>1 y ago) history of alcohol abuse, n 2 0 0.2
History of drug abuse, n 2 1 0.6
Plasma BDNF concentration at first measurement under placebo, mean (SD), pg/mL 3058.0 (1506.6) 2383.2 (1281.4) 0.08
Plasmal leptin concentration at first measurement under placebo, mean (SD), ng/mL 12.7 (9.4) 13.1 (7.9) 0.81
MADRS score at first measurement, mean (SD) 2.0 (2.6) 1.0 (2.8) 0.19
HAMD score at first measurement, mean (SD) 1.0 (1.4) 0.3 (0.6) 0.02*
EDE-Q score at first measurement, mean (SD) 6.3 (9.3) 1.7 (2.0) 0.01*
Abbreviations: BDNF, brain derived neurotrophic factor; BMI, Body Mass Index; BMI min, minimal Body Mass Index during disease; BMI max, maximal Body Mass In-
dex during disease; EDE-Q, Eating Disorder Examination-Questionnaire; HAMD, Hamilton Scale of Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; 
n.a., not applicable; * indicates a significant difference at P < .05.
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The current study investigated plasma BDNF and leptin 
levels in unmedicated subjects with rBN and assessed their 
association to reward-related behavior during an experimen-
tally induced depletion of central dopamine and norepineph-
rine stores. We found a positive association at a trend level 
between the AMPT-induced differences in plasma BDNF levels 
and reward learning in the whole study population that is com-
patible with a function of BDNF in reward-related behaviors. 
It has been demonstrated that BDNF and its tyrosine kinase 
receptor are expressed in dopaminergic neurons of the VTA 
and that BDNF is anterogradely transported to the NAc (Numan 
and Seroogy, 1999), which suggests a role for BDNF in modu-
lating reward. Specifically, BDNF levels in dopaminergic cells 
within the VTA/NAc pathway might be related to the neuroa-
daptive changes following reward responses in animal models. 
In line with this, BDNF stimulates the release of dopamine in 
mesencephalic neurons of rodents (Blochl and Sirrenberg, 1996), 
and BDNF infusions into the NAc of rats have shown that this 
dopamine release is associated with a facilitation of reward-
related stimuli (Horger et  al., 1999). In addition, recent work 
has shown that mutant mice depleted of central BDNF exhib-
ited a marked decrease in the evoked release of dopamine in 
the NAc and dorsal striatum (Cordeira et al., 2010). Notably, the 
VTA-specific deletion of the BDNF gene resulted in increased 
ingestion of a palatable, high-fat diet but not of a standard diet. 
These results suggest a positive modulation of hedonic eating 
by BDNF through increasing mesolimbic dopaminergic activity. 
In humans, initial evidence suggests a BDNF effect of dopamine-
mediated responses to reward in the VTA/NAc pathway (Pecina 
et al., 2014). The positive association at a trend level of AMPT-
induced changes in plasma BDNF levels and the corresponding 
changes in reward learning under a condition of experimentally 
Figure 1. Boxplots of plasma brain derived neurotrophic factor (BDNF) concentrations before and after catecholamine depletion in subjects with remitted bulimia 
nervosa (rBN) (n = 20) and healthy controls (n = 27). The first sample was drawn immediately before, the second one within 1 hour after eating a regular standardized 
breakfast. BN pre, rBN patients before treatment; BN post, rBN patients after treatment; HC pre, healthy controls before treatment; HC post, healthy controls after treat-
ment. (B) Alpha-methyl-para-tyrosine (AMPT)-induced differences in plasma BDNF levels plotted against the AMPT-induced differences in reward learning in subjects 
with rBN and healthy controls. Reward learning was defined as the difference in response bias between Block 1 and Block 3 of a probabilistic reward task. The Spear-
man rank correlation between the AMPT-induced differences in plasma BDNF levels and the AMPT-induced differences in reward learning approached significance 
(rho = 0.3, P = .05). (C) Boxplots of plasma leptin concentrations before and after catecholamine depletion in subjects with rBN (n = 20) and healthy controls (n = 27). The 
first sample was drawn immediately before, the second one within 1 hour after eating a regular standardized breakfast. HC 7:00 am = healthy controls before eating a 
standardized breakfast; HC 10 am = healthy controls after eating a standardized breakfast; rB 7 am = rBN patients before eating a standardized breakfast; rB 10 am = rBN 
patients after eating a standardized breakfast.
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depleted dopamine as found in our study supports the view of 
a tight connection between BDNF, dopamine, and reward also 
in humans.
With respect to the plasma BDNF levels, we found higher 
concentrations at the first measurement under placebo in rBN 
subjects compared with controls. Across all conditions, these 
levels were higher in rBN subjects compared with controls and 
higher in both groups under catecholamine depletion compared 
with placebo. Previous studies have found reduced BDNF con-
centrations in BN compared with controls (Nakazato et al., 2003; 
Monteleone et al., 2005; Yamada et al., 2012), but this reduction 
was not always significant (Saito et al., 2009) or even found in 
controls compared with BN (Mercader et  al., 2007). Our study 
differed in an important aspect from the aforementioned stud-
ies in that we measured subjects with BN in remission that 
were off medication. This allowed for an investigation without 
potential medication confounds and during a period of experi-
mentally induced eating disorder symptoms (Grob et al., 2013). 
During this relapse-like period, we did not observe a decrease of 
plasma BDNF concentrations; instead, the levels were higher in 
rBN compared with controls across conditions. Increased BDNF 
concentrations with respect to BN have previously been inter-
preted as high BDNF levels in the central nervous system that 
would alter eating behavior (Mercader et al., 2007). In line with 
this, BDNF infusions into the rodents brains have been reported 
to induce weight loss while increasing feeding and food retrieval 
(Lapchak and Hefti, 1992; Pelleymounter et  al., 1995; Martin-
Iverson and Altar, 1996). In addition, it has been found that mice 
with a heterozygous BDNF knockout display hyperphagia and 
obesity (Lyons et al., 1999; Kernie et al., 2000; Rios et al., 2001). 
However, it has been suggested that the site and dose of BDNF 
infusion has to be considered, since only intra-VTA but not NAc 
infusions produced weight loss in mice (Horger et  al., 1999). 
Further, a recent study in anorexia nervosa, an eating disorder 
closely related to BN, has reported on different levels of BDNF 
depending on the stage of disease. Specifically, BDNF concen-
trations were significantly higher in recovered compared with 
underweight patients and increased with short-term weight 
gain (Zwipp et  al., 2014). This might indicate that the higher 
plasma BDNF levels in rBN compared with controls found in our 
study might be a relevant factor in achieving remission.
Our study is the first to report on a decrease between pre-
prandial and postprandial plasma BDNF levels in rBN subjects 
and healthy controls. The interpretation of this finding is not 
straightforward, since BDNF has been suggested to induce appe-
tite suppression and weight loss through a central mechanism in 
previous animal studies (Lapchak and Hefti, 1992; Pelleymounter 
et al., 1995; Martin-Iverson and Altar, 1996). In humans, genetic 
BDNF polymorphisms are linked to severe obesity (Yeo et  al., 
2004; Friedel et al., 2005; Gray et al., 2006; Beckers et al., 2008; 
Burns et  al., 2010). Consequently, this finding challenges the 
current view that BDNF modulates appetite suppression (Unger 
et al., 2007). A possible explanation for this differential result in 
our study is that previous work has focused on the role of BDNF 
in obesity and corresponding overeating behavior, whereas the 
subjects assessed in the current study had BN in remission with 
a normal eating behavior.
The current study also investigated the association of reward 
learning and plasma leptin levels. Although leptin has been 
reported to modulate reward-related behavior by decreasing 
the firing of mesolimbic dopaminergic neurons as well as dopa-
mine release and concentrations in the NAc (Krugel et al., 2003), 
we did not find an association of reward learning and plasma 
leptin levels in the current study. We found that plasma leptin 
levels were comparable at the first measurement under placebo 
in both rBN and controls and that the increasing effect of the 
pharmacological manipulation with AMPT was evident in both 
groups. These results are in contrast to previous studies that 
have found reduced plasma and serum leptin levels in normal-
weight BN subjects (Jimerson et  al., 2000; Monteleone et  al., 
2000a 2000b; Monteleone et al., 2002a 2002b). One of these stud-
ies has also measured BN subjects in remission with a mean 
remission time comparable with our study and has confirmed 
the reduction of leptin levels in this sample (Jimerson et  al., 
2000). Monteleone and Maj (2013) have recently reviewed the role 
of leptin in BN. Based on their own findings (Monteleone et al., 
2000b; Monteleone et al., 2002a), these authors have suggested 
that the role of leptin as a peripheral signal of available energy 
stores seems to be preserved in subjects with BN, whereas its 
signal function of acute changes in the energy balance is lost 
(Monteleone and Maj, 2013). In line with this suggestion is our 
finding of a positive correlation of plasma leptin levels and BMI 
in subjects with rBN, which is also consistent with previous 
reports (reviewed in Monteleone and Maj, 2013). However, with 
respect to our conflicting findings of comparable plasma leptin 
levels in rBN and controls under placebo and higher levels under 
catecholamine depletion, it has to be considered that our study 
differed in an important aspect from the aforementioned stud-
ies, since we measured subjects with BN in remission during 
a pharmacological challenge with AMPT (Grob et al., 2013). The 
findings themselves might indicate that the plasma leptin levels 
are restored in remitted subjects with BN and are a relevant fac-
tor in achieving remission.
The current study had some limitations that merit com-
ment. Because of the relatively small sample size, the findings 
should be considered preliminary and should be replicated in 
larger samples in future studies. It should also be noted that 
the patients included in this study were in remission, so the 
findings may not necessarily apply to unremitted patients. The 
catecholamine-dependent association of plasma BDNF and 
reward learning was modest and only approached significance 
(P = .05). However, this effect was significant after excluding rBN 
subjects with a history of anorexia nervosa, suggesting that 
anorexia nervosa might be a confounder in this relationship. 
In addition, the fact that we measured peripheral and not cen-
tral BDNF and leptin levels as well as the fact that AMPT might 
have had peripheral effects should be considered. It is thus 
possible that a peripheral modulation of BDNF and leptin levels 
caused by AMPT might have contributed to the present find-
ings. Furthermore, it is important to note that the correlational 
analysis could not establish a causal relationship between 
AMPT-induced changes in plasma BDNF levels and reward 
learning. Finally, the specificity of our results was limited by 
the fact that AMPT reduces not only the synthesis of dopamine 
but also norepinephrine. Consequently, an influence of reduced 
norepinephrine on reward learning and BDNF and leptin levels 
cannot be entirely ruled out.
In conclusion, the current study reports on preliminary 
findings that suggest a catecholamine-dependent association 
of plasma BDNF and reward learning in subjects with rBN and 
controls. A role of leptin in reward learning is not supported by 
this study. However, leptin levels were sensitive to a depletion of 
catecholamine stores in both rBN and controls.
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